XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other. The following represents selected financial information for our segments for the three months ended January 31, 2025 and 2024 and as of January 31, 2025 and October 31, 2024 (in thousands):

  

   2025   2024 
   For the Three Months Ended
January 31,		 
   2025   2024 
Net loss:          
Cancer Vaccines  $(2,018)  $(1,756)
CAR-T Therapeutics   (1,177)   (1,525)
Other   (18)   (9)
Total  $(3,213)  $(3,290)
           
Total operating costs and expenses  $3,386   $3,609 
Less non-cash stock-based compensation   (1,055)   (1,260)
Operating costs and expenses excluding non-cash stock-based compensation  $2,331   $2,349 
Operating costs and expenses excluding non-cash stock-based compensation expense:          
Cancer Vaccines  $1,467   $1,213 
CAR-T Therapeutics   848    1,128 
Other   16    8 
Total  $2,331   $2,349 

  

   January 31,
2025		   October 31,
2024		 
Total assets:          
Cancer Vaccines  $11,863   $12,917 
CAR-T Therapeutics   6,885    8,535 
Other   158    139 
Total  $18,906   $21,591 

 

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.